ArticleJournal of hematology & oncology2022

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.

Muhammad Elnaggar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.